News and
Events
CURESPONSE Awarded European Patent for Functional Discovery of Novel Combination Therapy in Colorectal Cancer
CURESPONSE Joins Israel’s Health-Tech Roadshow to the U.S., Showcasing Innovation in Functional Precision Oncology
CURESPONSE Showcases Breakthrough Functional Oncology Platform at Tumour Models London Summit 2024
CURESPONSE to collaborate with EDX Medical Group plc, on marketing the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark.
Curesponse selected for ‘Israeli Innovation Dream Team’ 2024/2025
A New Publication Highlights the Use of cResponse in the Assessment of Response to Treatments for Pancreatic Cancer
Curesponse discusses with the Jerusalem Post its innovative cResponse™ test that helps tailor the optimal treatment for breast cancer patients.
Curesponse discuss with the Jerusalem Post its cResponse test that can predict which drugs will benefit individual cancer patients.
Curesponse Presents Positive Preliminary Clinical Results from a Multi-Center UK Study at AACR
Curesponse discusses its cancer prediction cResponse™ test with Ynet (in hebrew)
Want to know more?